ERLOTINIB

Trials studying ERLOTINIB

• phase2Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)completedn=21
• phase1A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutationactive not recruitingn=498
• phase2Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancercompletedn=156
• phase3AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancercompletedn=674
• phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720
• phase3A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Canceractive not recruitingn=453
• phase2A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutationscompletedn=168
• phase1Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplificationsactive not recruitingn=85